Document Detail


Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis.
MedLine Citation:
PMID:  21205969     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
CONTEXT: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is common, but trial evidence is conflicting and therapeutic options are controversial.
OBJECTIVE: To conduct a systematic review and network meta-analysis comparing mean symptom scores and treatment response among α-blockers, antibiotics, anti-inflammatory drugs, other active drugs (phytotherapy, glycosaminoglycans, finasteride, and neuromodulators), and placebo.
DATA SOURCES: We searched MEDLINE from 1949 and EMBASE from 1974 to November 16, 2010, using the PubMed and Ovid search engines.
STUDY SELECTION: Randomized controlled trials comparing drug treatments in CP/CPPS patients.
DATA EXTRACTION: Two reviewers independently extracted mean symptom scores, quality-of-life measures, and response to treatment between treatment groups. Standardized mean difference and random-effects methods were applied for pooling continuous and dichotomous outcomes, respectively. A longitudinal mixed regression model was used for network meta-analysis to indirectly compare treatment effects.
DATA SYNTHESIS: Twenty-three of 262 studies identified were eligible. Compared with placebo, α-blockers were associated with significant improvement in symptoms with standardized mean differences in total symptom, pain, voiding, and quality-of-life scores of -1.7 (95% confidence interval [CI], -2.8 to -0.6), -1.1 (95% CI, -1.8 to -0.3), -1.4 (95% CI, -2.3 to -0.5), and -1.0 (95% CI, -1.8 to -0.2), respectively. Patients receiving α-blockers or anti-inflammatory medications had a higher chance of favorable response compared with placebo, with pooled RRs of 1.6 (95% CI, 1.1-2.3) and 1.8 (95% CI, 1.2-2.6), respectively. Contour-enhanced funnel plots suggested the presence of publication bias for smaller studies of α-blocker therapies. The network meta-analysis suggested benefits of antibiotics in decreasing total symptom scores (-9.8; 95% CI, -15.1 to -4.6), pain scores (-4.4; 95% CI, -7.0 to -1.9), voiding scores (-2.8; 95% CI, -4.1 to -1.6), and quality-of-life scores (-1.9; 95% CI, -3.6 to -0.2) compared with placebo. Combining α-blockers and antibiotics yielded the greatest benefits compared with placebo, with corresponding decreases of -13.8 (95% CI, -17.5 to -10.2) for total symptom scores, -5.7 (95% CI, -7.8 to -3.6) for pain scores, -3.7 (95% CI, -5.2 to -2.1) for voiding, and -2.8 (95% CI, -4.7 to -0.9) for quality-of-life scores.
CONCLUSIONS: α-Blockers, antibiotics, and combinations of these therapies appear to achieve the greatest improvement in clinical symptom scores compared with placebo. Anti-inflammatory therapies have a lesser but measurable benefit on selected outcomes. However, beneficial effects of α-blockers may be overestimated because of publication bias.
Authors:
Thunyarat Anothaisintawee; John Attia; J Curtis Nickel; Sangsuree Thammakraisorn; Pawin Numthavaj; Mark McEvoy; Ammarin Thakkinstian
Related Documents :
16164589 - Cluster randomized controlled trials.
12734019 - A simple method for analyzing data from a randomized trial with a missing binary outcome.
21466749 - Predicting the onset of major depression in primary care: international validation of a...
21093749 - Cosmeceuticals: practical applications.
21422759 - Human tissue kallikrein promoted activation of the ipsilesional sensorimotor cortex aft...
19029209 - Use of biological assignment in hematopoietic stem cell transplantation clinical trials.
10796759 - Systemic treatments for metastatic cutaneous melanoma.
7040659 - Effects of acupuncture in bronchial asthma: preliminary communication.
9641509 - A self-report thompson articular index: what does it measure?
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  JAMA     Volume:  305     ISSN:  1538-3598     ISO Abbreviation:  JAMA     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-05     Completed Date:  2011-01-07     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  United States    
Other Details:
Languages:  eng     Pagination:  78-86     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / therapeutic use*
Anti-Bacterial Agents / therapeutic use*
Anti-Inflammatory Agents / therapeutic use*
Chronic Disease
Humans
Male
Pelvic Pain / drug therapy*
Placebos
Prostatitis / drug therapy*
Publication Bias
Quality of Life
Syndrome
Treatment Outcome
Urination
Grant Support
ID/Acronym/Agency:
//Canadian Institutes of Health Research
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Anti-Bacterial Agents; 0/Anti-Inflammatory Agents; 0/Placebos
Comments/Corrections
Comment In:
JAMA. 2011 Apr 6;305(13):1298; author reply 1298-9   [PMID:  21467281 ]
Evid Based Med. 2011 Oct;16(5):143-4   [PMID:  21518708 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors...
Next Document:  Maximal subthalamic beta hypersynchrony of the local field potential in Parkinson's disease is locat...